This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients With Metastatic Esophageal Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2005 by Edelman, Martin, M.D..
Recruitment status was:  Active, not recruiting
Bristol-Myers Squibb
Information provided by:
Edelman, Martin, M.D. Identifier:
First received: May 14, 2002
Last updated: June 23, 2005
Last verified: January 2005

This study is for patients with esophageal cancer that has spread to other areas. The purpose of this study is to:

  1. Determine how well a combination of taxol, UFT, and leucovorin work in these patients,
  2. Determine the survival of patients with metastatic esophageal carcinoma treated with this combination of drugs.
  3. Identify the side effects of this drug combination.

Condition Intervention Phase
Esophageal Neoplasm Drug: UFT (Tegafur/Uracil) Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Edelman, Martin, M.D.:


Ages Eligible for Study:   18 Years to 79 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologic proof of esophageal cancer
  • No more than one prior non-taxane chemotherapy regimen for either treatment of localized disease or metastatic disease AND they may not have received a regimen containing low dose continuous infusion of 5-FU (i.e. >5 days of infusion/cycle), capecitabine or UFT
  • No prior therapy with UFT+/-leucovorin, a taxane, capecitabine, low dose continuous infusion of 5-FU or ethynyl uracil.
  • Radiographic or physical examination documentation of metastatic disease
  • No major surgery within the 2 weeks preceding the start of treatment and fully recovered from any complications of surgery
  • No radiation within 2 weeks of beginning chemotherapy.
  • No chemotherapy within 4 weeks of beginning treatment.
  • Patients must wait at least 6 weeks after receiving BCNU or Mitomycin-C.
  • Minimum life expectancy of 3 months
  • Informed consent given
  • Laboratory values within limits set by study.


  • More than one prior chemotherapy regimen for metastatic disease
  • Current serious medical or psychiatric illness that would prevent informed consent or intensive treatment
  • >grade 1 peripheral sensory or motor neuropathy
  • Pregnant
  • Patient is taking the drug Sorivudine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00037089

United States, Maryland
University of Maryland Cancer Center
Baltimore, Maryland, United States, 21201
Sponsors and Collaborators
Edelman, Martin, M.D.
Bristol-Myers Squibb
  More Information Identifier: NCT00037089     History of Changes
Other Study ID Numbers: BMS-200604
UMCC 0110g
Study First Received: May 14, 2002
Last Updated: June 23, 2005

Additional relevant MeSH terms:
Esophageal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents processed this record on August 18, 2017